Vienna-based Hookipa Biotech AG has raised €20 million from institutional investors to bring a vaccine candidate for cytomegalovirus into the clinic and to build a pipeline of products for oncology and infectious disease. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
